Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-01-05
DOI
https://doi.org/10.1182/blood.2025030722
Citations
1
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
35.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Stephanie von Harsdorf, Lino Lars Teichmann, Axel Benner, Markus P. Radsak et al.
1 citations
Blood
Acute Myeloid Leukemia Research
35.41
article

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Stephanie von Harsdorf, Lino Lars Teichmann, Axel Benner, Markus P. Radsak, Gregor Aschauer, W Vogel, Michael Lübbert, A Ganser, Konstanze Döhner, Bernd Hertenstein, David Nachbaur, Lars Bullinger, Katharina S. S. Götze, Lars R. Fransecky, Peter Paschka, Anika Schrade, Walter Fiedler, V I Gaidzik, Jörg Westermann, Roland Schroers, Elisabeth Koller, Michael Heuser, Felicitas R Thol, Ulrich Germing, Maral Saadati, Stefanie Weißhaar, Uwe M Martens, Albert Wölfler, Andrea Corbacioglu, Hans-Joachim Tischler, Daniela Späth, Hartmut Döhner
article en
1 citations

Abstract

No abstract available for this paper.
Blood
Innsbruck Medical University (AT), Universität Hamburg (DE), University of Freiburg (DE), German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), Medical University of Graz (AT), Heidelberg University (DE), University Hospital Bonn (DE), University Medical Center Freiburg (DE), Medizinische Hochschule Hannover (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Universitätsklinikum Tübingen (DE), Hanusch Hospital (AT), University Medical Center Hamburg-Eppendorf (DE), Universitätsklinikum Knappschaftskrankenhaus Bochum (DE), University Hospital Schleswig-Holstein (DE), University Cancer Center Hamburg (DE), Klinikum Ludwigshafen (DE), AGO Austria (AT), Kliniken Essen-Mitte (DE), University Hospital in Halle (DE), Klinikum Bremen-Mitte (DE), University Hospital Ulm (DE), SLK-Kliniken Heilbronn (DE), Johannes Wesling Klinikum Minden (DE), Heinrich Heine University Düsseldorf (DE), Technical University of Munich (DE), Charité - Universitätsmedizin Berlin (DE), University of Lübeck (DE)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Ariad Pharmaceuticals, Celgene, Jazz Pharmaceuticals, BeiGene, Incyte, Syndax Pharmaceuticals, Astellas Pharma, Servier, Swedish Orphan Biovitrum, MorphoSys, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 2%
Acute Myeloid Leukemia Research
35.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.